RESUMEN
Corynantheidine, a minor alkaloid found in Mitragyna speciosa (Korth.) Havil, has been shown to bind to opioid receptors and act as a functional opioid antagonist, but its unique contribution to the overall properties of kratom remains relatively unexplored. The first validated bioanalytical method for the quantification of corynantheidine in rat plasma is described. The method was linear in the dynamic range from 1-500â¯ng/mL, requires a small plasma sample volume (25⯵L), and a simple protein precipitation method for extraction of the analyte. The separation was achieved with Waters BEH C18 2.1â¯×â¯50â¯mm column and the 3-minute gradient of 10â¯mM ammonium acetate buffer (pHâ¯=â¯3.5) and acetonitrile as mobile phase. The method was validated in terms of accuracy, precision, selectivity, sensitivity, recovery, stability, and dilution integrity. It was applied to the analysis of the male Sprague Dawley rat plasma samples obtained during pharmacokinetic studies of corynantheidine administered both intravenously (I.V.) and orally (P.O.) (2.5â¯mg/kg and 20â¯mg/kg, respectively). The non-compartmental analysis performed in Certara Phoenix® yielded the following parameters: clearance 884.1⯱â¯32.3â¯mL/h, apparent volume of distribution 8.0⯱â¯1.2â¯L, exposure up to the last measured time point 640.3⯱â¯24.0â¯h*ng/mL, and a mean residence time of 3.0⯱â¯0.2â¯h with I.V. dose. The maximum observed concentration after a P.O. dose of 213.4⯱â¯40.4â¯ng/mL was detected at 4.1⯱â¯1.3â¯h with a mean residence time of 8.8⯱â¯1.8â¯h. Absolute oral bioavailability was 49.9⯱â¯16.4 %. Corynantheidine demonstrated adequate oral bioavailability, prolonged absorption and exposure, and an extensive extravascular distribution. In addition, imaging mass spectrometry analysis of the brain tissue was performed to evaluate the distribution of the compound in the brain. Corynantheidine was detected in the corpus callosum and some regions of the hippocampus.
Asunto(s)
Alcaloides/farmacocinética , Mitragyna/química , Mitragyna/metabolismo , Antagonistas de Narcóticos/farmacocinética , Extractos Vegetales/farmacocinética , Animales , Disponibilidad Biológica , Técnicas Biosensibles , Recolección de Muestras de Sangre , Cromatografía Líquida de Alta Presión , Límite de Detección , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrometría de Masas en TándemRESUMEN
The design and discovery of JDTic as a potent and selective kappa opioid receptor antagonist used the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine pharmacophore as the lead structure. In order to determine if the 3-methyl or 4-methyl groups were necessary in JDTic and JDTic analogs for antagonistic activity, compounds 4a-c, and 4d-f which have either the 3-methyl or both the 3- and 4-methyl groups removed, respectively, from JDTic and analogs were synthesized and evaluated for their in vitro opioid receptor antagonist activities using a [(35)S]GTPγS binding assay. Other ADME properties were also assessed for selected compounds. These studies demonstrated that neither the 3-methyl or 3,4-dimethyl groups present in JDTic and analogs are required to produce potent and selective κ opioid receptor antagonists.
Asunto(s)
Diseño de Fármacos , Antagonistas de Narcóticos/síntesis química , Piperidinas/química , Receptores Opioides kappa/antagonistas & inhibidores , Tetrahidroisoquinolinas/química , Animales , Permeabilidad de la Membrana Celular/efectos de los fármacos , Perros , Evaluación Preclínica de Medicamentos , Semivida , Células de Riñón Canino Madin Darby , Antagonistas de Narcóticos/metabolismo , Antagonistas de Narcóticos/farmacocinética , Piperidinas/metabolismo , Piperidinas/farmacocinética , Unión Proteica , Receptores Opioides kappa/metabolismo , Tetrahidroisoquinolinas/metabolismo , Tetrahidroisoquinolinas/farmacocinéticaRESUMEN
A new series of novel opioid ligands have been designed and synthesized based on the 4-anilidopiperidine scaffold containing a 5-substituted tetrahydronaphthalen-2yl)methyl group with different N-phenyl-N-(piperidin-4-yl)propionamide derivatives to study the biological effects of these substituents on µ and δ opioid receptor interactions. Recently our group reported novel 4-anilidopiperidine analogues, in which several aromatic ring-contained amino acids were conjugated with N-phenyl-N-(piperidin-4-yl)propionamide and examined their biological activities at the µ and δ opioid receptors. In continuation of our efforts in these novel 4-anilidopiperidine analogues, we took a peptidomimetic approach in the present design, in which we substituted aromatic amino acids with tetrahydronaphthalen-2yl methyl moiety with amino, amide and hydroxyl substitutions at the 5th position. In in vitro assays these ligands, showed very good binding affinity and highly selective toward the µ opioid receptor. Among these, the lead ligand 20 showed excellent binding affinity (2 nM) and 5000 fold selectivity toward the µ opioid receptor, as well as functional selectivity in GPI assays (55.20 ± 4.30 nM) and weak or no agonist activities in MVD assays. Based on the in vitro bioassay results the lead compound 20 was chosen for in vivo assessment for efficacy in naïve rats after intrathecal administration. Compound 20 was not significantly effective in alleviating acute pain. This discrepancy between high in vitro binding affinity, moderate in vitro activity, and low in vivo activity may reflect differences in pharmacodynamics (i.e., engaging signaling pathways) or pharmacokinetics (i.e., metabolic stability). In sum, our data suggest that further optimization of this compound 20 is required to enhance in vivo activity.
Asunto(s)
Amidas/química , Receptores Opioides/química , Amidas/síntesis química , Amidas/farmacocinética , Analgésicos Opioides/síntesis química , Analgésicos Opioides/química , Analgésicos Opioides/farmacología , Animales , Conducta Animal/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Semivida , Ligandos , Masculino , Antagonistas de Narcóticos/síntesis química , Antagonistas de Narcóticos/química , Antagonistas de Narcóticos/farmacocinética , Unión Proteica , Ratas , Ratas Sprague-Dawley , Receptores Opioides/metabolismo , Receptores Opioides delta/química , Receptores Opioides delta/metabolismo , Receptores Opioides mu/química , Receptores Opioides mu/metabolismoRESUMEN
Pain is a negative emotional experience that is modulated by a variety of psychological factors through different inhibitory systems. For example, endogenous opioids and cannabinoids have been found to be involved in stress and placebo analgesia. Here we show that when the meaning of the pain experience is changed from negative to positive through verbal suggestions, the opioid and cannabinoid systems are co-activated and these, in turn, increase pain tolerance. We induced ischemic arm pain in healthy volunteers, who had to tolerate the pain as long as possible. One group was informed about the aversive nature of the task, as done in any pain study. Conversely, a second group was told that the ischemia would be beneficial to the muscles, thus emphasizing the usefulness of the pain endurance task. We found that in the second group pain tolerance was significantly higher compared to the first one, and that this effect was partially blocked by the opioid antagonist naltrexone alone and by the cannabinoid antagonist rimonabant alone. However, the combined administration of naltrexone and rimonabant antagonized the increased tolerance completely. Our results indicate that a positive approach to pain reduces the global pain experience through the co-activation of the opioid and cannabinoid systems. These findings may have a profound impact on clinical practice. For example, postoperative pain, which means healing, can be perceived as less unpleasant than cancer pain, which means death. Therefore, the behavioral and/or pharmacological manipulation of the meaning of pain can represent an effective approach to pain management.
Asunto(s)
Péptidos Opioides/fisiología , Dolor/psicología , Comunicación Persuasiva , Receptores de Cannabinoides/fisiología , Recompensa , Adulto , Brazo/irrigación sanguínea , Actitud Frente a la Salud , Antagonistas de Receptores de Cannabinoides/efectos adversos , Antagonistas de Receptores de Cannabinoides/farmacocinética , Cultura , Método Doble Ciego , Femenino , Humanos , Isquemia/complicaciones , Masculino , Naltrexona/efectos adversos , Naltrexona/farmacocinética , Antagonistas de Narcóticos/efectos adversos , Antagonistas de Narcóticos/farmacocinética , Dolor/etiología , Resistencia Física , Piperidinas/efectos adversos , Piperidinas/farmacocinética , Pirazoles/efectos adversos , Pirazoles/farmacocinética , Rimonabant , Sugestión , Factores de Tiempo , Adulto JovenRESUMEN
Neuropathic pain is a debilitating condition that is often difficult to treat using conventional pharmacological interventions and the exact mechanisms involved in the establishment and maintenance of this type of chronic pain have yet to be fully elucidated. The present studies examined the effect of chronic nerve injury on µ-opioid receptors and receptor-mediated G-protein activity within the supraspinal brain regions involved in pain processing of mice. Chronic constriction injury (CCI) reduced paw withdrawal latency, which was maximal at 10 days post-injury. [d-Ala2,(N-Me)Phe4,Gly5-OH] enkephalin (DAMGO)-stimulated [(35)S]GTPγS binding was then conducted at this time point in membranes prepared from the rostral ACC (rACC), thalamus and periaqueductal grey (PAG) of CCI and sham-operated mice. Results showed reduced DAMGO-stimulated [(35)S]GTPγS binding in the thalamus and PAG of CCI mice, with no change in the rACC. In thalamus, this reduction was due to decreased maximal stimulation by DAMGO, with no difference in EC(50) values. In PAG, however, DAMGO E(max) values did not significantly differ between groups, possibly due to the small magnitude of the main effect. [(3)H]Naloxone binding in membranes of the thalamus showed no significant differences in B(max) values between CCI and sham-operated mice, indicating that the difference in G-protein activation did not result from differences in µ-opioid receptor levels. These results suggest that CCI induced a region-specific adaptation of µ-opioid receptor-mediated G-protein activity, with apparent desensitization of the µ-opioid receptor in the thalamus and PAG and could have implications for treatment of neuropathic pain.
Asunto(s)
Proteínas de Unión al GTP/metabolismo , Receptores Opioides mu/metabolismo , Ciática/patología , Tálamo/metabolismo , Analgésicos Opioides/farmacología , Animales , Constricción , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas/fisiología , Encefalina Ala(2)-MeFe(4)-Gli(5)/farmacología , Guanosina 5'-O-(3-Tiotrifosfato)/farmacocinética , Hiperalgesia/etiología , Masculino , Ratones , Naloxona/farmacocinética , Antagonistas de Narcóticos/farmacocinética , Umbral del Dolor/fisiología , Unión Proteica/efectos de los fármacos , Ciática/complicaciones , Isótopos de Azufre/farmacocinética , Tálamo/fisiopatología , Factores de Tiempo , Tritio/farmacocinéticaRESUMEN
This research is based on the recognized need for an in vitro release method for drug implants that better simulate physiological conditions at the site of implantation ('biorelevance'). In this paper, we describe the evaluation of a 'biorelevant' approach for in vitro drug release testing of a biodegradable implant of naltrexone in a pre-clinical stage of development. A miniature, capillary cell culture device was modified and tested as a biorelevant alternative for a standard commercially available flow-through cell. The real-time data generated through 90 days indicated a 48% lower rate of release for the capillary system. The profiles using both systems followed zero-order kinetics after an initial period of burst release. In vitro release data from the capillary device resulted in a 1-to-1 correlation with dog plasma pharmacokinetic data, and furthermore, the capillary device potentially simulated the lag-time in absorption more effectively than the flow-through cell. Scanning electron micrographs revealed that the sheath was continuous with no signs of cracks at the end of in vitro and in vivo studies. However, at the interface of the sheath and the core, intercalating, "finger-like" projections were observed consistent with penetration of the medium. No macroscopic or clinical toxicity signs were observed during the in vivo implantation study.
Asunto(s)
Reactores Biológicos , Evaluación Preclínica de Medicamentos/instrumentación , Implantes de Medicamentos , Naltrexona/química , Antagonistas de Narcóticos/química , Tecnología Farmacéutica/instrumentación , Animales , Química Farmacéutica , Difusión , Perros , Composición de Medicamentos , Implantes de Medicamentos/efectos adversos , Implantes de Medicamentos/química , Diseño de Equipo , Reacción a Cuerpo Extraño/etiología , Reacción a Cuerpo Extraño/patología , Cinética , Modelos Biológicos , Naltrexona/efectos adversos , Naltrexona/sangre , Naltrexona/farmacocinética , Antagonistas de Narcóticos/efectos adversos , Antagonistas de Narcóticos/sangre , Antagonistas de Narcóticos/farmacocinética , Reproducibilidad de los Resultados , Solubilidad , Tejido Subcutáneo/ultraestructura , Propiedades de SuperficieRESUMEN
Using PET with the opioidergic ligand [11C]diprenorphine, the authors demonstrate decreased tracer binding in the pineal gland of cluster headache patients vs healthy volunteers. Opioid receptor availability in the hypothalamus and cingulate cortex depended on the duration of the headache disorder. Therefore, the pathophysiology of cluster headache may relate to opioidergic dysfunction in circuitries generating the biologic clock.
Asunto(s)
Cefalalgia Histamínica/diagnóstico por imagen , Diprenorfina/farmacocinética , Hipotálamo/diagnóstico por imagen , Antagonistas de Narcóticos/farmacocinética , Glándula Pineal/diagnóstico por imagen , Adulto , Radioisótopos de Carbono , Cefalalgia Histamínica/patología , Lateralidad Funcional , Humanos , Hipotálamo/patología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Glándula Pineal/patología , Tomografía de Emisión de Positrones , RadiografíaRESUMEN
The phenolic hydroxy group of opiate-derived ligands is of known importance for biological activity. We have developed a SAR study around LY255582 by comparing the effect of the hydroxy group in the 2- and 4-position of the phenyl ring. Also, we have proved that the 3-position of the phenyl ring is optimal for opioid activity. Furthermore, we have successfully replaced the hydroxy group in LY255582 by carbamate and carboxamide groups. The new analogs have high affinity for the opioid receptors comparable to the corresponding phenol. Carboxamide analog 12 has an improved metabolism profile and proved to be efficacious in in vivo studies.
Asunto(s)
Antagonistas de Narcóticos/síntesis química , Piperidinas/síntesis química , Administración Oral , Animales , Ciclohexanos , Evaluación Preclínica de Medicamentos , Conducta Alimentaria/efectos de los fármacos , Ligandos , Hígado/metabolismo , Antagonistas de Narcóticos/farmacocinética , Antagonistas de Narcóticos/farmacología , Dolor/prevención & control , Fenoles , Piperidinas/farmacocinética , Piperidinas/farmacología , Ensayo de Unión Radioligante , Ratas , Relación Estructura-ActividadRESUMEN
The opioid antagonist nalmefene offers an alternative to traditional pharmacological treatments for alcoholism. The present study was designed to investigate the relationship between nalmefene plasma concentration and central mu-opioid receptor occupancy after a clinically effective dose (20 mg, orally). Pharmacokinetics and mu-opioid receptor occupancy of nalmefene after single and repeated dosing over 7 days was studied in 12 healthy subjects. Serial blood samples were obtained after both dosings, and pharmacokinetic parameters for nalmefene and main metabolites were determined. Central mu-opioid receptor occupancy of nalmefene was measured with positron emission tomography (PET) and [(11)C]carfentanil at four time points (3, 26, 50, 74 h) after both dosings. Nalmefene was rapidly absorbed in all subjects. The mean t(1/2) of nalmefene was 13.4 h after single and repeated dosing. The accumulation of nalmefene and its main metabolites in plasma during the repeated dosing period was as expected for a drug with linear pharmacokinetics, and steady-state was reached for all analytes. Both nalmefene dosings resulted in a very high occupancy at mu-opioid receptors (87-100%), and the decline in the occupancy was similar after both dosings but clearly slower than the decline in the plasma concentration of nalmefene or metabolites. High nalmefene occupancy (83-100%) persisted at 26 h after the dosings. The prolonged mu-opioid receptor occupancy by nalmefene indicates slow dissociation of the drug from mu-opioid receptors. These results support the rational of administering nalmefene when needed before alcohol drinking, and they additionally suggest that a high mu-opioid receptor occupancy can be maintained when nalmefene is taken once daily.
Asunto(s)
Naltrexona/análogos & derivados , Antagonistas de Narcóticos/farmacocinética , Receptores Opioides mu/efectos de los fármacos , Adolescente , Adulto , Analgésicos Opioides/farmacocinética , Área Bajo la Curva , Núcleo Caudado/metabolismo , Electrocardiografía/efectos de los fármacos , Fentanilo/análogos & derivados , Fentanilo/farmacocinética , Glucurónidos/metabolismo , Humanos , Masculino , Naltrexona/farmacocinética , Tomografía de Emisión de Positrones , Corteza Prefrontal/metabolismo , Tálamo/metabolismoRESUMEN
A diester prodrug of nalbuphine, sebacoyl dinalbuphine (SDN), and its long-acting formulation are currently being developed to prolong the duration of nalbuphine. A comparative in vitro hydrolysis study was conducted for SDN in rat, rabbit, dog, and human blood. Both SDN and nalbuphine in blood or plasma were measured by high-performance liquid chromatography. The hydrolysis rates of SDN in blood were ranked as follows: rat > rabbit > human > dog. The rapid formation of nalbuphine in the blood accounted for almost 100% of the prodrug, which supported the contention that nalbuphine is the major metabolite after SDN hydrolysis. The hydrolysis profiles of SDN were similar both in plasma and in red blood cells when compared in the blood. In vitro release results of SDN long-acting formulation showed that the rate-limited step of SDN hydrolysis to nalbuphine in blood is the penetration of SDN from oil into the blood. After intravenous administration of SDN in sesame oil into rats, nalbuphine quickly appeared in plasma and, thereafter, exhibited monoexponential decay. Pharmaceutical dosage forms affecting the drug disposition kinetics were demonstrated after intravenous administration. The AUC of nalbuphine was significantly higher and clearance was significantly lower, without changes in the t(1/2) of nalbuphine after intravenous dosing of SDN in sesame oil when compared with that of intravenous dosing with nalbuphine HCl in rats. Overall, these results suggest that SDN fulfilled the original pro-soft drug design in which the prodrug can rapidly metabolize to nalbuphine, and no other unexpected compounds were apparent in the blood.